Literature DB >> 12799406

Impact of HIV infection and HAART on serum lipids in men.

Sharon A Riddler1, Ellen Smit, Stephen R Cole, Rui Li, Joan S Chmiel, Adrian Dobs, Frank Palella, Barbara Visscher, Rhobert Evans, Lawrence A Kingsley.   

Abstract

CONTEXT: Alterations in serum lipid values have been widely reported among persons infected with human immunodeficiency virus (HIV) type 1 treated with highly active antiretroviral therapy (HAART), but no data have yet been reported on changes from preseroconversion lipid values.
OBJECTIVE: To describe changes in serum cholesterol levels associated with HIV infection and antiretroviral medication exposure, and 1-time assessment of triglyceride levels post-HAART initiation. DESIGN, SETTING, AND PARTICIPANTS: The Multicenter AIDS Cohort Study, a prospective study in which homosexual and bisexual men were enrolled and from which 50 of 517 HIV seroconverters were drawn for the analysis herein, who later initiated HAART, involving measurements of stored serum samples obtained between 1984 and 2002. MAIN OUTCOME MEASURES: Changes in levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) at 6 time points during an average of 12 years; 1-time assessment of triglyceride levels from the third post-HAART clinic visit.
RESULTS: Among the 50 men, notable declines in mean serum TC (-30 mg/dL [-0.78 mmol/L]), HDL-C (-12 mg/dL [-0.31 mmol/L]), and LDL-C values (-22 mg/dL [-0.57 mmol/L]) were observed after HIV infection. Following HAART initiation, there were large increases in mean TC and LDL-C values (50 and 21 mg/dL [1.30 and 0.54 mmol/L], respectively); however, the mean changes from the preseroconversion values were 20 mg/dL (0.52 mmol/L) (95% confidence interval [CI], -1 to 41) and -1 mg/dL (-0.03 mmol/L) (95% CI, -25 to 22), respectively. Mean HDL-C remained below baseline levels throughout follow-up. The median value (interquartile range) of triglycerides was 225 mg/dL (2.54 mmol/L) (147-331 mg/dL).
CONCLUSIONS: Before treatment, HIV infection results in substantial decreases in serum TC, HDL-C, and LDL-C levels. Subsequent HAART initiation is associated with increases in TC and LDL-C but little change in HDL-C. Increases in TC and LDL-C observed after about 3 years of HAART possibly represent a return to preinfection serum lipid levels after accounting for expected age-related changes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12799406     DOI: 10.1001/jama.289.22.2978

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  204 in total

Review 1.  Plant glutaredoxins: still mysterious reducing systems.

Authors:  N Rouhier; E Gelhaye; J-P Jacquot
Journal:  Cell Mol Life Sci       Date:  2004-06       Impact factor: 9.261

2.  Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects.

Authors:  B M Bergersen; L Sandvik; J N Bruun; S Tonstad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-28       Impact factor: 3.267

Review 3.  Management of the metabolic effects of HIV and HIV drugs.

Authors:  Todd T Brown; Marshall J Glesby
Journal:  Nat Rev Endocrinol       Date:  2011-09-20       Impact factor: 43.330

4.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

Review 5.  The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.

Authors:  Oliver P Flint; Mustafa A Noor; Paul W Hruz; Phil B Hylemon; Kevin Yarasheski; Donald P Kotler; Rex A Parker; Aouatef Bellamine
Journal:  Toxicol Pathol       Date:  2009-01-26       Impact factor: 1.902

Review 6.  Acute coronary syndrome in HIV patients: from pathophysiology to clinical practice.

Authors:  Enrico Cerrato; Fabrizio D'Ascenzo; Giuseppe Biondi-Zoccai; Pierluigi Omedè; Claudio Moretti; Stefania Cicalini; Gurumurthy Parthasarathi; Imad Sheiban; Fiorenzo Gaita
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

7.  Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of age.

Authors:  Agnes Langat; Sarah Benki-Nugent; Dalton Wamalwa; Ken Tapia; Evelyn Ngugi; Lara Diener; Barbra A Richardson; Ann Melvin; Grace C John-Stewart
Journal:  Pediatr Infect Dis J       Date:  2013-07       Impact factor: 2.129

8.  Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy.

Authors:  Erdembileg Anuurad; Asha Thomas-Geevarghese; Sridevi Devaraj; Jeanine Albu; Robert Minolfo; Wafaa M El-Sadr; Guijing Lu; Wahida Karmally; Lars Berglund
Journal:  Atherosclerosis       Date:  2007-11-09       Impact factor: 5.162

9.  Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

Authors:  Ighovwerha Ofotokun; Lumine H Na; Raphael J Landovitz; Heather J Ribaudo; Grace A McComsey; Catherine Godfrey; Francesca Aweeka; Susan E Cohn; Manish Sagar; Daniel R Kuritzkes; Todd T Brown; Kristine B Patterson; Michael F Para; Randi Y Leavitt; Angelina Villasis-Keever; Bryan P Baugh; Jeffrey L Lennox; Judith S Currier
Journal:  Clin Infect Dis       Date:  2015-03-12       Impact factor: 9.079

10.  Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients.

Authors:  S A Pereira; J R Batuca; U Caixas; T Branco; J Delgado-Alves; I Germano; F Lampreia; E C Monteiro
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.